Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the best NASDAQ stocks under $10 to buy. As of December 15, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has a ‘Hold’ or equivalent rating from ...

A new study estimates the environmental impact of AI in 2025 and calls for more transparency from companies on their pollution and water consumption. A new study estimates the environmental impact of ...

Fears about AI data centers’ water use have exploded. Experts say the reality is far more complicated than people think. When I called him to talk more about AI and water, Masley emphasized that he’s ...

At MAI (Microsoft AI), we don’t just build AI tools, we care about how real people interact with them. So as 2025 wraps up, we’ve gone headfirst into a mountain of de-identified data, searching for ...

On CNBC's “Mad Money Lightning Round,” on Thursday, Jim Cramer said Recursion Pharmaceuticals (NASDAQ: RXRX) has been “horrendous” and he does not like to recommend horrendous stocks. On the earnings ...

There was an error while loading. Please reload this page. A public-safe case study. Reports built on top of a clean T-SQL query layer. This documents the process and ...

To better understand which social media platforms Americans use, Pew Research Center surveyed 5,022 U.S. adults from Feb. 5 to June 18, 2025. SSRS conducted this National Public Opinion Reference ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Recursion, Roche, and its Genentech subsidiary have unveiled the latest product of their nearly four-year artificial intelligence (AI) drug discovery collaboration, a whole-genome map of specialized ...

TORONTO — The pitch — a 96-mph sinker — was supposed to start on the inner half of the plate and move to the insider corner, forcing George Springer, already favoring his aching back knee, to either ...